Image de couverture de livre

Research on the mechanism of HOPX‐HDAC2 interaction inducing differentiation blockage in acute myeloid leukemia

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Fang He, Yan Tu, Lihong Ni
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax
par: Stefano Cordella, et autres
Publié: (2024)

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia
par: María Turos‐Cabal, et autres
Publié: (2024)

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect
par: Jinrong Yang, et autres
Publié: (2024)

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia
par: Yuan Sun, et autres
Publié: (2024)

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
par: Sudhir Manda, et autres
Publié: (2024)

Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis
par: Rong Wang, et autres
Publié: (2024)

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis
par: Lin‐Ya Wang, et autres
Publié: (2024)

Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis
par: Marie Anne‐Catherine Neumann, et autres
Publié: (2024)

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications
par: N. Polverelli, et autres
Publié: (2024)

Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects
par: Daniele Cattaneo, et autres
Publié: (2024)

The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group
par: Xinyu Li, et autres
Publié: (2024)

ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia
par: Zong‐Yan Shi, et autres
Publié: (2024)

Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
par: Hanyin Wang, et autres
Publié: (2024)

Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study
par: Benjamin J. Lee, et autres
Publié: (2024)

802 | A STUDY ON THE MECHANISM OF THE NOVEL HIGHLY SELECTIVE HDAC INHIBITOR PURINOSTAT MESYLATE IN DOUBLE‐HIT LYMPHOMA AND ITS THERAPEUTIC POTENTIAL COMBINATION WITH VENETOCLAX
par: J. Wang, et autres
Publié: (2025)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
par: Maria Anele Romeo, et autres
Publié: (2024)

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study
par: Anna Panovská, et autres
Publié: (2024)

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
par: Nayla Mouawad, et autres
Publié: (2024)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
par: Francesca Romana Mauro, et autres
Publié: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
par: Hidehiro Itonaga, et autres
Publié: (2024)

95 | A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XNW5004, A SELECTIVE EZH2 INHIBITOR, IN SUBJECTS WITH RELAPSED/ REFRACTORY NON‐HODGKIN LYMPHOMA
par: W. Zheng, et autres
Publié: (2025)

61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)
par: Y. Song, et autres
Publié: (2025)

646 | ZANUBRUTINIB PLUS R‐CHOP IMPROVES THE TREATMENT EFFECT OF NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA WITH DOUBLE EXPRESSION OF MYC AND BCL‐2
par: M. Zhang, et autres
Publié: (2025)

642 | REAL‐WORLD EFFICACY AND SAFETY OF GLOFITAMAB IN CHINESE PATIENTS WITH R/R DLBCL: HIGH RESPONSE RATES IN HIGH‐RISK POPULATIONS
par: Z. Qian, et autres
Publié: (2025)

Clinical and Prognostic Impact of Allelic Status in EZH2 ‐Mutated Myeloid Neoplasms
par: Muhamad Oum, et autres
Publié: (2025)

49 | COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
par: C. S. Tam, et autres
Publié: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
par: Rui Sun, et autres
Publié: (2026)

805 | PRE‐CLINICAL DEVELOPMENT OF CAR‐T CELLS TARGETING A LYTIC EBV ANTIGEN gp350 FOR THERAPY OF EBV‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA
par: Y. Li, et autres
Publié: (2025)

165 | LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABLE, MULTI‐CENTER PHASE IB/II STUDY (LINCH TRIAL)
par: Q. Cai, et autres
Publié: (2025)

145 | SONROTOCLAX (BGB‐11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB (ZANU) DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE 1 RESULTS
par: C. Y. Cheah, et autres
Publié: (2025)

514 | CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?
par: H. Zhu, et autres
Publié: (2025)

720 | THE TREATMENT EVOLUTION OF CLASSIC HODGKIN LYMPHOMA OVER TWO DECADES IN CHINA: REAL‐WORLD EXPERIENCES OF AN ACADEMIC CENTER
par: Z. He, et autres
Publié: (2025)

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia
par: Xiaoyu Zhang, et autres
Publié: (2025)

697 | NOVEL SMALL MOLECULAR TARGET AGENTS WITH HD‐MTX‐BASED REGIMENS IMPROVED REMISSION RATES WITHOUT PROLONGING PFS IN NEWLY DIAGNOSED PCNSL
par: H. Zhu, et autres
Publié: (2025)

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
par: Francesco Passamonti, et autres
Publié: (2026)

294 | CLINICAL PRACTICE PATTERN AND OUTCOMES IN DLBCL WITH DISTINCT GENETIC SUBTYPES: A LARGE‐SCALE REAL‐WORLD STUDY FROM CHINA
par: P. Xu, et autres
Publié: (2025)

818 | INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DLBCL: A PHASE I/II STUDY (PRIDE STUDY)
par: P. Xu, et autres
Publié: (2025)

484 | SINGLE‐CELL ANALYSIS OF CIRCULATING IMMUNE HETEROGENEITY IN DIFFUSE LARGE B‐CELL LYMPHOMA HIGHLIGHTS DISTINCT IMMUNE CELL SIGNATURES IN IMMUNOTHERAPY
par: S. Zhang, et autres
Publié: (2025)

501 | NOVEL ROLE OF CHIDAMIDE IN TAM REPROGRAMMING AND IMMUNOTHERAPY ENHANCEMENT THROUGH RNA SPLICING
par: C. Wang, et autres
Publié: (2025)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
par: Fuli Fan, et autres
Publié: (2025)